Tyruko

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease.[3] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin.[3] It is given by intravenous infusion every 28 days.[3] The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–b... [wikipedia]